Effect of opicapone and entacapone on daily pattern of motor fluctuations in Parkinson’s disease patients
Objective: To evaluate the effect of opicapone (OPC) 50 mg versus entacapone (ENT) on daily pattern of motor fluctuations. Background: OPC, a once-daily catechol-O-methyltransferase inhibitor,…Efficacy and safety/tolerability of opicapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations
Objective: To evaluate the potential added benefit of opicapone (OPC), compared with placebo (PLC) and entacapone (ENT), in catechol-O-methyltransferase inhibitor (COMTi)-naïve Parkinson’s disease (PD) patients…Onset of Drug-Related Adverse Events in Parkinson’s Disease Patients with Motor Fluctuations Treated with Opicapone in Clinical Practice: OPTIPARK Post-Hoc Analysis
Objective: This post-hoc analysis investigated the onset of treatment-emergent adverse events (TEAEs) that were considered at least possibly related to opicapone (OPC) treatment. Background: OPC…Effect of opicapone and entacapone on levodopa short duration response
Objective: To evaluate the effect of opicapone (OPC) 50 mg versus entacapone (ENT) on levodopa short duration response (SDR). Background: OPC, a once-daily catechol-O-methyltransferase inhibitor,…Beta-adrenoreceptor medications and risk of Parkinson’s disease
Objective: To review and analyze the associations between β-adrenoreceptor medications and risk of Parkinson's disease. Background: Distinctive Lewy body mainly composed of α-synuclein is an…Quantitative study of T-type Ca2+ channels in the subthalamic nucleus neurons towards Parkinson’s disease
Objective: From the pathophysiological perspectives, Parkinson’s disease (PD) can be viewed as a prototypical disorder of “brain arrhythmias”. Therefore, the modulation of relevant ion channels…Vitamin D assessment in patents with Parkinson’s disease
Objective: Analysis of the effectiveness of vitamin D in patients with PD depending on clinical manifestations and concentration levels of 25 (OH) D. Background: Recent…Levodopa Dose Equivalency for Opicapone and Safinamide
Objective: To provide a levodopa dose equivalency (LED) for opicapone and safinamide. Background: Tomlinson at al., provided a schedule to calculate LED of the different…Opicapone and entacapone as add-on therapy to the treatment of infusions of levodopa-carbidopa intestinal gel in patients with advanced Parkinson’s disease
Objective: To study the effect of COMT inhibitors (opicapone and entacapone) in Parkinson's disease (PD) patients on levodopa-carbidopa intestinal gel (LCIG) and an insufficient control of…Opicapone management: A 2-year follow up real- life practice study
Objective: The aim of this work is to show our clinical experience with opicapone in real practice in a cohort of 68 parkinsonian patients followed…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.